본문으로 건너뛰기
← 뒤로

The rise of bispecific T-cell engager (BsTCE) antibodies: a potentially game-changing approach for breast cancer therapy?

2/5 보강
Drug discovery today 📖 저널 OA 13.8% 2023: 0/1 OA 2024: 0/1 OA 2025: 2/8 OA 2026: 2/19 OA 2023~2026 2026 Vol.31(3) p. 104670 Monoclonal and Polyclonal Antibodies
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-30
OpenAlex 토픽 · Monoclonal and Polyclonal Antibodies Research CAR-T cell therapy research HER2/EGFR in Cancer Research

Gudavalekar PU, Khandave PY, Shalini S, Selvaraju S, Pande AH

📝 환자 설명용 한 줄

Over the past decade, there has been exponential growth in the development of bispecific T-cell engager (BsTCE) antibodies, along with their immunotherapeutic applications in oncology.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Pravin U Gudavalekar, Prakash Y. Khandave, et al. (2026). The rise of bispecific T-cell engager (BsTCE) antibodies: a potentially game-changing approach for breast cancer therapy?. Drug discovery today, 31(3), 104670. https://doi.org/10.1016/j.drudis.2026.104670
MLA Pravin U Gudavalekar, et al.. "The rise of bispecific T-cell engager (BsTCE) antibodies: a potentially game-changing approach for breast cancer therapy?." Drug discovery today, vol. 31, no. 3, 2026, pp. 104670.
PMID 41967765 ↗

Abstract

Over the past decade, there has been exponential growth in the development of bispecific T-cell engager (BsTCE) antibodies, along with their immunotherapeutic applications in oncology. BsTCEs are an emerging class of bispecific antibodies that represent a novel T-cell-based immunotherapy, altering the treatment landscape for solid tumors by introducing novel functionality that redirects T cells to tumor-associated antigens to induce tumor cell killing. In breast cancer, one of the leading causes of death worldwide, human epidermal growth factor receptor 2 (HER2) is a well-studied tumor-associated antigen, while several other emerging targets are being evaluated. This review aims to provide insights into the vital role of BsTCEs and the dire need to target emerging antigens in breast cancer, particularly for addressing ongoing challenges related to drug resistance.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반